20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
3 citations
,
July 2025 in “BIOMED natural and applied science” Drug repurposing can create safer, cheaper treatments by finding new uses for existing drugs.
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Samcyprone ointment is effective for treating common warts if a sensitization reaction occurs first.
1 citations
,
July 2023 in “International Journal of Molecular Sciences” Old psychiatric drugs are increasingly being used for new purposes, and technologies like SmartCube® help create new drugs.
26 citations
,
September 2024 in “Perspectives in Clinical Research” Drug repurposing offers faster, cheaper drug development but faces challenges like safety, ethics, and funding.
11 citations
,
October 2024 in “Cell Death Discovery” 4-aminopyridine helps heal burn wounds faster by reducing inflammation and promoting new blood vessel growth.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
75 citations
,
June 2007 in “Journal of Biological Chemistry” MT-DADMe-ImmA can selectively kill head and neck cancer cells without harming normal cells.
November 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” 4-aminopyridine helps skin wounds heal faster and better.
February 2026 in “Clinical Cancer Research” The combined treatment helped prevent hair loss and promoted full hair regrowth in breast cancer patients after chemotherapy.
19 citations
,
September 2013 in “Psychoneuroendocrinology” Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.
1 citations
,
May 2022 in “The FASEB journal” The document concludes that biotin, folate, and RGD peptides are promising for targeting cancer cells with prodrugs, but the conjugates are not yet tested for use.
September 2025 in “International Journal of Pharmacy and Biomedical Engineering” Drug repurposing finds new uses for existing drugs, speeding up treatment availability and reducing costs.
August 2010 in “Oncology Times” Provenge extends prostate cancer survival by about 4 months.
May 2025 in “International Journal of Science and Research (IJSR)” Stopping azathioprine led to full hair regrowth and recovery in 2.5 months.
June 2023 in “Frontiers in Cardiovascular Medicine” Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.
1 citations
,
March 2023 in “Medicine” The combination therapy is effective and well-tolerated for treating esophageal cancer.
38 citations
,
February 2006 in “British Journal of Clinical Pharmacology” The study found that combining different databases gives a better estimate of drug side effects in hospitals.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” 2 citations
,
November 2025 in “Pharmacology Research & Perspectives” Avacopan may cause unexpected side effects, so early monitoring is important.
70 citations
,
August 2019 in “European Journal of Medicinal Chemistry”
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
56 citations
,
January 2023 in “Genes & Diseases” Repurposing existing drugs and using micronutrients may effectively target cancer stem cells and improve cancer treatment.
6 citations
,
May 2013 in “Journal of Clinical Oncology” Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
8 citations
,
April 2023 in “World Journal of Clinical Cases” Crystalloids are recommended for fluid resuscitation, and early enteral feeding is preferred for nutrition in acute pancreatitis.
8 citations
,
January 1977 in “Acta Haematologica” The treatment was effective for advanced non-Hodgkin's lymphomas.
April 2024 in “DAHUDER Medical journal” Ocrelizumab may cause pancreatitis in some patients.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
142 citations
,
March 2019 in “Frontiers in Cellular Neuroscience” The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.